|
|
Last Modified: 7/14/2005  First Published: 11/24/2002 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II, Phase I
|
|
|
|
Prevention
|
|
|
|
Completed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
AMC-035 NCT00052897, AMC-035
|
|
|
|
|
|
|
|
Last Modified: 9/3/2008  First Published: 1/26/2003 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Prevention
|
|
|
|
Completed
|
|
|
|
17 and over
|
|
|
|
NCI
|
|
|
|
GOG-0197 GOG-0197, NCT00054041
|
|
|
|
|
|
|
|
Last Modified: 9/3/2008  First Published: 4/23/2003 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
BWH-000-P-CONS01 NCI-3074, NCT00060099, 3074
|
|
|
|
|
|
|
|
Last Modified: 9/3/2008  First Published: 12/23/2003 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Prevention
|
|
|
|
Completed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
AECM-0309225 NCI-5850, NCT00075569, 5850
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Prevention, Treatment
|
|
|
|
Completed
|
|
|
|
2 to 18
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
Stressgen SGN-00101-0005 SGN-00101-0005, NCT00038714
|
|
|
|
|
|
|
|
Last Modified: 4/12/2007  First Published: 8/24/2004 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Prevention
|
|
|
|
Closed
|
|
|
|
18 to 50
|
|
|
|
NCI
|
|
|
|
UCIRVINE-02-55 UCIRVINE-2002-2758, NCT00091130
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase I
|
|
|
|
Prevention
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
HspE7-00101-0601 NCT00493545
|
|
|
|